-
1
-
-
80052092055
-
Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats
-
Abe K, Toba M, Alzoubi A, Koubsky K, Ito M, Ota H, Gairhe S, Gerthoffer WT, Fagan KA, McMurtry IF, Oka M. 2011. Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats. Am. J. Respiratory Cell and Mol. Biology 45: 804-808.
-
(2011)
Am. J. Respiratory Cell and Mol. Biology
, vol.45
, pp. 804-808
-
-
Abe, K.1
Toba, M.2
Alzoubi, A.3
Koubsky, K.4
Ito, M.5
Ota, H.6
Gairhe, S.7
Gerthoffer, W.T.8
Fagan, K.A.9
McMurtry, I.F.10
Oka, M.11
-
2
-
-
84866008200
-
Sunitinib, a receptor tyrosine kinase inhibitor, increases blood pressure in rats without associated changes in cardiac structure and function
-
2011. doi: 10.1111/j.1755-5922.2011.00278.x. [Epub ahead of print]
-
Blasi E, Heyen J, Patyna S, Hemkens M, Ramirez D, John-Baptiste A, Steidl-Nichols J, McHarg A. 2011. Sunitinib, a receptor tyrosine kinase inhibitor, increases blood pressure in rats without associated changes in cardiac structure and function. Cardiovasc. Ther. 2011. doi: 10.1111/j.1755-5922.2011.00278.x. [Epub ahead of print]
-
(2011)
Cardiovasc. Ther.
-
-
Blasi, E.1
Heyen, J.2
Patyna, S.3
Hemkens, M.4
Ramirez, D.5
John-Baptiste, A.6
Steidl-Nichols, J.7
McHarg, A.8
-
3
-
-
76749151845
-
Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes
-
Braam SR, Tertoolen L, van de Stolpe A, Meyer T, Passier R, Mummery CL. 2010. Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res. 4: 107-116.
-
(2010)
Stem Cell Res.
, vol.4
, pp. 107-116
-
-
Braam, S.R.1
Tertoolen, L.2
van de Stolpe, A.3
Meyer, T.4
Passier, R.5
Mummery, C.L.6
-
4
-
-
50949132320
-
Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics
-
Chen M, Kerkelä R, Force T. 2008. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 117: 84-95.
-
(2008)
Circulation
, vol.117
, pp. 84-95
-
-
Chen, M.1
Kerkelä, R.2
Force, T.3
-
5
-
-
74049125665
-
Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics
-
Cheng H, Force T. 2010. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ. Res. 106: 21-34.
-
(2010)
Circ. Res.
, vol.106
, pp. 21-34
-
-
Cheng, H.1
Force, T.2
-
6
-
-
36849023013
-
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
-
Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen J, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen M. 2007. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370: 2011-2019.
-
(2007)
Lancet
, vol.370
, pp. 2011-2019
-
-
Chu, T.F.1
Rupnick, M.A.2
Kerkela, R.3
Dallabrida, S.M.4
Zurakowski, D.5
Nguyen, L.6
Woulfe, K.7
Pravda, E.8
Cassiola, F.9
Desai, J.10
George, S.11
Morgan, J.A.12
Harris, D.M.13
Ismail, N.S.14
Chen, J.15
Schoen, F.J.16
Van den Abbeele, A.D.17
Demetri, G.D.18
Force, T.19
Chen, M.20
more..
-
7
-
-
68549134977
-
Assessment of two external telemetry systems (PhysioJacket and JET) in beagle dogs with telemetry implants
-
Chui RW, Fosdick A, Conner R, Jiang J, Bruenner BA, Vargas HM. 2009. Assessment of two external telemetry systems (PhysioJacket and JET) in beagle dogs with telemetry implants. J. Pharmacol. Toxicol. Methods 60: 58-68.
-
(2009)
J. Pharmacol. Toxicol. Methods
, vol.60
, pp. 58-68
-
-
Chui, R.W.1
Fosdick, A.2
Conner, R.3
Jiang, J.4
Bruenner, B.A.5
Vargas, H.M.6
-
8
-
-
81255142147
-
Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations
-
Cohen JD, Babiarz JE, Abrams RM, Guo L, Kameoka S, Chiao E, Taunton J, Kolaja KL. 2011. Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations. Toxicol. Appl. Pharmacol. 257: 74-83.
-
(2011)
Toxicol. Appl. Pharmacol.
, vol.257
, pp. 74-83
-
-
Cohen, J.D.1
Babiarz, J.E.2
Abrams, R.M.3
Guo, L.4
Kameoka, S.5
Chiao, E.6
Taunton, J.7
Kolaja, K.L.8
-
9
-
-
74549192747
-
The Langendorff Heart
-
Dhein S, Delmar M, Mohr FW (eds). Springer Berlin Heidelberg: New York. Part 2,2
-
Dhein S. 2005. The Langendorff Heart. In Practical Methods in Cardiovascular Research, Dhein S, Delmar M, Mohr FW (eds). Springer Berlin Heidelberg: New York. Part 2, 2, 155-172.
-
(2005)
Practical Methods in Cardiovascular Research
, pp. 155-172
-
-
Dhein, S.1
-
10
-
-
69849085146
-
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis
-
Di Lorenzo G, Autorino R, Bruni G, Carteni G, Ricevuto E, Tudini M, Ficorella C, Romano C, Aieta M, Giordano A, Giuliano M, Gonnella A, De Nunzio C, Rizzo M, Montesarchio V, Ewer M, De Placido S. 2009. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann. Oncol. 20: 1535-1542.
-
(2009)
Ann. Oncol.
, vol.20
, pp. 1535-1542
-
-
Di Lorenzo, G.1
Autorino, R.2
Bruni, G.3
Carteni, G.4
Ricevuto, E.5
Tudini, M.6
Ficorella, C.7
Romano, C.8
Aieta, M.9
Giordano, A.10
Giuliano, M.11
Gonnella, A.12
De Nunzio, C.13
Rizzo, M.14
Montesarchio, V.15
Ewer, M.16
De Placido, S.17
-
11
-
-
34247480545
-
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
-
Force T, Krause DS, Van Etten RA. 2007. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer 7: 332-344.
-
(2007)
Nat. Rev. Cancer
, vol.7
, pp. 332-344
-
-
Force, T.1
Krause, D.S.2
Van Etten, R.A.3
-
12
-
-
77957680164
-
Differences in effects on myocardium and mitochondria by angiogenic inhibitors suggest separate mechanisms of cardiotoxicity
-
French KJ, Coatney RW, Renninger JP, Hu CX, Gales TL, Zhao S, Storck LM, Davis CB, McSurdy-Freed J, Chen E, Frazier KS. 2010. Differences in effects on myocardium and mitochondria by angiogenic inhibitors suggest separate mechanisms of cardiotoxicity. Toxicol. Pathol. 38: 691-702.
-
(2010)
Toxicol. Pathol.
, vol.38
, pp. 691-702
-
-
French, K.J.1
Coatney, R.W.2
Renninger, J.P.3
Hu, C.X.4
Gales, T.L.5
Zhao, S.6
Storck, L.M.7
Davis, C.B.8
McSurdy-Freed, J.9
Chen, E.10
Frazier, K.S.11
-
13
-
-
33749003166
-
Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction
-
Gelb BD, Tartaglia M. 2006. Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. Hum. Mol. Genet. 15: R220-R226.
-
(2006)
Hum. Mol. Genet.
, vol.15
-
-
Gelb, B.D.1
Tartaglia, M.2
-
14
-
-
25444484658
-
Imatinib for the treatment of pulmonary arterial hypertension
-
Ghofrani HA, Seeger W, Grimminger F. 2005. Imatinib for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 353: 1412-1413.
-
(2005)
N. Engl. J. Med.
, vol.353
, pp. 1412-1413
-
-
Ghofrani, H.A.1
Seeger, W.2
Grimminger, F.3
-
15
-
-
84855246295
-
Human stem cell-derived cardiomyocytes for pharmacological and toxicological modeling
-
Harding SE. 2011. Human stem cell-derived cardiomyocytes for pharmacological and toxicological modeling. Ann. N. Y. Acad. Sci. 1245: 48-49.
-
(2011)
Ann. N. Y. Acad. Sci.
, vol.1245
, pp. 48-49
-
-
Harding, S.E.1
-
16
-
-
77950042300
-
The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity
-
Hasinoff BB. 2010. The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. Toxicol. Appl. Pharmacol. 244: 190-195.
-
(2010)
Toxicol. Appl. Pharmacol.
, vol.244
, pp. 190-195
-
-
Hasinoff, B.B.1
-
17
-
-
57349174523
-
Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib
-
Hasinoff BB, Patel D, O'Hara KA. 2008. Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib. Mol. Pharmacol. 74: 1722-1728.
-
(2008)
Mol. Pharmacol.
, vol.74
, pp. 1722-1728
-
-
Hasinoff, B.B.1
Patel, D.2
O'Hara, K.A.3
-
18
-
-
82355169061
-
A multifaceted evaluation of imatinib-induced cardiotoxicity in the rat
-
Herman EH, Knapton A, Rosen E, Thompson K, Rosenzweig B, Estis J, Agee S, Lu Q, Todd JA, Lipshultz S, Hasinoff B, Zhang J. 2011. A multifaceted evaluation of imatinib-induced cardiotoxicity in the rat. Toxicol. Pathol. 39: 1091-1106.
-
(2011)
Toxicol. Pathol.
, vol.39
, pp. 1091-1106
-
-
Herman, E.H.1
Knapton, A.2
Rosen, E.3
Thompson, K.4
Rosenzweig, B.5
Estis, J.6
Agee, S.7
Lu, Q.8
Todd, J.A.9
Lipshultz, S.10
Hasinoff, B.11
Zhang, J.12
-
19
-
-
0036213057
-
Mixed signals in heart failure: cancer rules
-
Hoshijima M, Chien KR. 2002. Mixed signals in heart failure: cancer rules. J. Clin. Invest. 109: 849-855.
-
(2002)
J. Clin. Invest.
, vol.109
, pp. 849-855
-
-
Hoshijima, M.1
Chien, K.R.2
-
20
-
-
84865760057
-
Mechanistic investigation of imatinib-induced cardiac toxicity and the involvement of c-Abl kinase
-
doi: 10.1093/toxsci/kfs192, published online on May 28, 2012.
-
Hu W, Lu S, Mcalpine I, Jamieson J, Lee D, Marroquin L, Heyen J, Jessen BA. 2012. Mechanistic investigation of imatinib-induced cardiac toxicity and the involvement of c-Abl kinase. Toxicol. Sci. doi: 10.1093/toxsci/kfs192, published online on May 28, 2012.
-
(2012)
Toxicol. Sci.
-
-
Hu, W.1
Lu, S.2
Mcalpine, I.3
Jamieson, J.4
Lee, D.5
Marroquin, L.6
Heyen, J.7
Jessen, B.A.8
-
21
-
-
84875927801
-
-
ICH S7A.Safety Pharmacology Studies for Human Pharmaceuticals [WWW document]. URL(accessed 18 July 2012)
-
ICH S7A. 2000. Safety Pharmacology Studies for Human Pharmaceuticals [WWW document]. URL http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7A/Step4/S7A_Guideline.pdf (accessed 18 July 2012).
-
(2000)
-
-
-
22
-
-
84875938989
-
-
ICH S7B. Non-clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals [WWW document]. URL(accessed 18 July 2012)
-
ICH S7B. 2005. Non-clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals [WWW document]. URL http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7B/Step4/S7B_Guideline.pdf (accessed 18 July 2012).
-
(2005)
-
-
-
23
-
-
84875921546
-
-
ICH S9. Nonclinical Evaluation for Anticancer Pharmaceuticals [WWW document]. URL(accessed 18 July 2012)
-
ICH S9. 2009. Nonclinical Evaluation for Anticancer Pharmaceuticals [WWW document]. URL http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S9/Step4/S9_Step4_Guideline.pdf (accessed 18 July 2012).
-
(2009)
-
-
-
24
-
-
77957231200
-
Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels
-
Kappers MHW, van Esch JHM, Sluiter W, Sleijfer S, Danser AHJ, van den Meiracker AH. 2010. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 56: 675-681.
-
(2010)
Hypertension
, vol.56
, pp. 675-681
-
-
Kappers, M.H.W.1
van Esch, J.H.M.2
Sluiter, W.3
Sleijfer, S.4
Danser, A.H.J.5
van den Meiracker, A.H.6
-
25
-
-
38049018155
-
A quantitative analysis of kinase inhibitor selectivity
-
Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP. 2008. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26: 127-132.
-
(2008)
Nat. Biotechnol.
, vol.26
, pp. 127-132
-
-
Karaman, M.W.1
Herrgard, S.2
Treiber, D.K.3
Gallant, P.4
Atteridge, C.E.5
Campbell, B.T.6
Chan, K.W.7
Ciceri, P.8
Davis, M.I.9
Edeen, P.T.10
Faraoni, R.11
Floyd, M.12
Hunt, J.P.13
Lockhart, D.J.14
Milanov, Z.V.15
Morrison, M.J.16
Pallares, G.17
Patel, H.K.18
Pritchard, S.19
Wodicka, L.M.20
Zarrinkar, P.P.21
more..
-
26
-
-
33746845181
-
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
-
Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, Van Etten RA, Alroy J, Jean-Bernard Durand J-B, Force T. 2006. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 12: 908-916.
-
(2006)
Nat. Med.
, vol.12
, pp. 908-916
-
-
Kerkela, R.1
Grazette, L.2
Yacobi, R.3
Iliescu, C.4
Patten, R.5
Beahm, C.6
Walters, B.7
Shevtsov, S.8
Pesant, S.9
Clubb, F.J.10
Rosenzweig, A.11
Salomon, R.N.12
Van Etten, R.A.13
Alroy, J.14
Jean-Bernard Durand, J.-B.15
Force, T.16
-
27
-
-
74049092701
-
Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase
-
Kerkela R, Woulfe KC, Durand J, Vagnozzi R, Kramer D, Chu TF, Beahm C, Chen M, Force T. 2009. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin. Transl. Sci. 2: 15-25.
-
(2009)
Clin. Transl. Sci.
, vol.2
, pp. 15-25
-
-
Kerkela, R.1
Woulfe, K.C.2
Durand, J.3
Vagnozzi, R.4
Kramer, D.5
Chu, T.F.6
Beahm, C.7
Chen, M.8
Force, T.9
-
28
-
-
57149145794
-
Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling
-
Klein M, Schermuly RT, Ellinghaus P, Milting H, Riedl B, Nikolova S, Pullamsetti SS, Weissmann N, Dony E, Savai R, Ghofrani HA, Grimminger F, Busch AE, Schäfer S. 2008. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 118: 2081-2090.
-
(2008)
Circulation
, vol.118
, pp. 2081-2090
-
-
Klein, M.1
Schermuly, R.T.2
Ellinghaus, P.3
Milting, H.4
Riedl, B.5
Nikolova, S.6
Pullamsetti, S.S.7
Weissmann, N.8
Dony, E.9
Savai, R.10
Ghofrani, H.A.11
Grimminger, F.12
Busch, A.E.13
Schäfer, S.14
-
29
-
-
77955435768
-
The new high- sensitivity cardiac troponin T assay improves risk assessment in acute coronary syndromes
-
Lindahl B, Venge P, James S. 2010. The new high- sensitivity cardiac troponin T assay improves risk assessment in acute coronary syndromes. Am. Heart J. 160: 224-229.
-
(2010)
Am. Heart J.
, vol.160
, pp. 224-229
-
-
Lindahl, B.1
Venge, P.2
James, S.3
-
30
-
-
73949151268
-
Echocardiographic examination in rats and mice
-
Liu J, Rigel DF. 2009. Echocardiographic examination in rats and mice. Methods Mol. Biol. 573: 139-155.
-
(2009)
Methods Mol. Biol.
, vol.573
, pp. 139-155
-
-
Liu, J.1
Rigel, D.F.2
-
31
-
-
84862798153
-
Evaluation of subchronic toxicity of SIM010603, a potent inhibitor of receptor tyrosine kinase, after 28-day repeated oral administration in SD rats and beagle dogs
-
Mao Y, Xia Z, Zhang X, Zong Y, Zhu L, Yuan B, Lu C. 2012. Evaluation of subchronic toxicity of SIM010603, a potent inhibitor of receptor tyrosine kinase, after 28-day repeated oral administration in SD rats and beagle dogs. Food Chem. Tox. 50: 1256-1270.
-
(2012)
Food Chem. Tox.
, vol.50
, pp. 1256-1270
-
-
Mao, Y.1
Xia, Z.2
Zhang, X.3
Zong, Y.4
Zhu, L.5
Yuan, B.6
Lu, C.7
-
32
-
-
84868156647
-
Cardiovascular events (CVEs) associated with tyrosine kinase inhibitor (TKI) therapy in patients with metastatic renal cell carcinoma (mRCC) at a regional cancer center
-
abstr e16040
-
McGhie J, Mackenzie MJ, Winquist E, Ernst S, Sax L, O'Brien P. 2009. Cardiovascular events (CVEs) associated with tyrosine kinase inhibitor (TKI) therapy in patients with metastatic renal cell carcinoma (mRCC) at a regional cancer center. J. Clin. Oncol. 27(suppl): abstr e16040.
-
(2009)
J. Clin. Oncol.
, vol.27
, Issue.SUPPL
-
-
McGhie, J.1
Mackenzie, M.J.2
Winquist, E.3
Ernst, S.4
Sax, L.5
O'Brien, P.6
-
33
-
-
77956045289
-
Evaluation of blood pressure measurement using a miniature blood pressure transmitter with jacketed external telemetry in cynomolgus monkeys
-
McMahon C, Mitchell AZ, Klein JL, Jenkins AC, Sarazan RD. 2010. Evaluation of blood pressure measurement using a miniature blood pressure transmitter with jacketed external telemetry in cynomolgus monkeys. J. Pharmacol. Toxicol. Methods 62: 127-135.
-
(2010)
J. Pharmacol. Toxicol. Methods
, vol.62
, pp. 127-135
-
-
McMahon, C.1
Mitchell, A.Z.2
Klein, J.L.3
Jenkins, A.C.4
Sarazan, R.D.5
-
35
-
-
84868121468
-
The Working Heart
-
Dhein S, Delmar M, Mohr FW (eds). Springer Berlin Heidelberg: New York. Part 2, 2
-
Merx M, Schrader J. 2005. The Working Heart. In Practical Methods in Cardiovascular Research, Dhein S, Delmar M, Mohr FW (eds). Springer Berlin Heidelberg: New York. Part 2, 2, 173-189.
-
(2005)
Practical Methods in Cardiovascular Research
, pp. 173-189
-
-
Merx, M.1
Schrader, J.2
-
36
-
-
0018186901
-
Evidence for non-infiltrative cardiomyopathy in acute leukaemia and lymphoma. A clinical and echocardiographic study
-
Mir MA. 1978. Evidence for non-infiltrative cardiomyopathy in acute leukaemia and lymphoma. A clinical and echocardiographic study. Br. Heart J. 40: 725-733.
-
(1978)
Br. Heart J.
, vol.40
, pp. 725-733
-
-
Mir, M.A.1
-
37
-
-
40749109217
-
Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension
-
Moreno-Vinasco L, Gomberg-Maitland M, Maitland ML, Desai AA, Singleton PA, Sammani S, Sam L, Liu Y, Husain AN, Lang RM, Ratain MJ, Lussier YA, Garcia JG. 2008. Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol. Genomics 33: 278-291.
-
(2008)
Physiol. Genomics
, vol.33
, pp. 278-291
-
-
Moreno-Vinasco, L.1
Gomberg-Maitland, M.2
Maitland, M.L.3
Desai, A.A.4
Singleton, P.A.5
Sammani, S.6
Sam, L.7
Liu, Y.8
Husain, A.N.9
Lang, R.M.10
Ratain, M.J.11
Lussier, Y.A.12
Garcia, J.G.13
-
38
-
-
84875935014
-
-
Nilotinib.EMA Scientific Discussion [WWW document]. URL(accessed 18 July 2012)
-
Nilotinib. 2007. EMA Scientific Discussion [WWW document]. URL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000798/WC500034398.pdf (accessed 18 July 2012).
-
(2007)
-
-
-
39
-
-
34250212715
-
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
-
Nissen SE, Wolski K. 2007. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356: 2457-2471.
-
(2007)
N. Engl. J. Med.
, vol.356
, pp. 2457-2471
-
-
Nissen, S.E.1
Wolski, K.2
-
41
-
-
63749090726
-
Launching a novel preclinical infrastructure: Comparative oncology trials consortium directed therapeutic targeting of TNFα to cancer vasculature
-
Paoloni MC, Tandle A, Mazcko C, Hanna E, Kachala S, LeBlanc A, Newman S, Vail D, Henry C, Thamm D, Sorenmo K, Hajitou A, Pasqualini R, Arap W, Khanna C, Libutti SK. 2009. Launching a novel preclinical infrastructure: Comparative oncology trials consortium directed therapeutic targeting of TNFα to cancer vasculature. PLoS One 4: e4972.
-
(2009)
PLoS One
, vol.4
-
-
Paoloni, M.C.1
Tandle, A.2
Mazcko, C.3
Hanna, E.4
Kachala, S.5
LeBlanc, A.6
Newman, S.7
Vail, D.8
Henry, C.9
Thamm, D.10
Sorenmo, K.11
Hajitou, A.12
Pasqualini, R.13
Arap, W.14
Khanna, C.15
Libutti, S.K.16
-
42
-
-
31344456635
-
The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors
-
Peterson JT. 2006. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc. Res. 69: 677-687.
-
(2006)
Cardiovasc. Res.
, vol.69
, pp. 677-687
-
-
Peterson, J.T.1
-
43
-
-
26444540768
-
Reversal of experimental pulmonary hypertension by PDGF inhibition
-
Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, Grimminger F. 2005. Reversal of experimental pulmonary hypertension by PDGF inhibition. J. Clin. Invest. 115: 2811-2821.
-
(2005)
J. Clin. Invest.
, vol.115
, pp. 2811-2821
-
-
Schermuly, R.T.1
Dony, E.2
Ghofrani, H.A.3
Pullamsetti, S.4
Savai, R.5
Roth, M.6
Sydykov, A.7
Lai, Y.J.8
Weissmann, N.9
Seeger, W.10
Grimminger, F.11
-
44
-
-
55949123335
-
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma
-
Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, Schmidinger H. 2008. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 26: 5204-5212.
-
(2008)
J. Clin. Oncol.
, vol.26
, pp. 5204-5212
-
-
Schmidinger, M.1
Zielinski, C.C.2
Vogl, U.M.3
Bojic, A.4
Bojic, M.5
Schukro, C.6
Ruhsam, M.7
Hejna, M.8
Schmidinger, H.9
-
47
-
-
84875926514
-
-
Sutent.FDA NDA Pharmacology Review [WWW document]. URL(accessed 18 July 2012)
-
Sutent. 2006. FDA NDA Pharmacology Review [WWW document]. URL http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021938_S000_Sutent_PharmR.pdf (accessed 18 July 2012).
-
(2006)
-
-
-
48
-
-
84875962881
-
-
SUTENT®(sunitinib malate). The FDA Approved Label [WWW document]. URL (or United States Product Information 2011) (accessed 18 July 2012)
-
SUTENT® (sunitinib malate). 2011. The FDA Approved Label [WWW document]. URL http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021938s13s17s18lbl.pdf (or United States Product Information 2011) (accessed 18 July 2012).
-
(2011)
-
-
-
49
-
-
84875959741
-
-
VOTRIENT®Data sheet of New Zealand "Medsafe" [WWW document]. URL(accessed 18 July 2012)
-
VOTRIENT®. 2012. Data sheet of New Zealand "Medsafe" [WWW document]. URL http://www.medsafe.govt.nz/profs/datasheet/v/votrienttab.pdf (accessed 18 July 2012).
-
(2012)
-
-
-
50
-
-
77955267778
-
Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies
-
Wolf A, Couttet P, Dong M, Grenet O, Heron M, Junker U, Laengle U, Ledieu D, Marrer E, Nussher A, Persohn E, Pognan F, Rivière G-J, Roth DR, Trendelenburg C, Tsao J, Roman D. 2010. Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies. Leuk. Res. 34: 1180-1188.
-
(2010)
Leuk. Res.
, vol.34
, pp. 1180-1188
-
-
Wolf, A.1
Couttet, P.2
Dong, M.3
Grenet, O.4
Heron, M.5
Junker, U.6
Laengle, U.7
Ledieu, D.8
Marrer, E.9
Nussher, A.10
Persohn, E.11
Pognan, F.12
Rivière, G.-J.13
Roth, D.R.14
Trendelenburg, C.15
Tsao, J.16
Roman, D.17
|